Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole Dry Powder for Inhalation for Prevention of Invasive Mould Disease in Acute Leukemia Patients with Neutropenia
2019-002408-42Phase 3Completed
- Sponsor
- SMB Laboratoires
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Invasive mold disease (IMD) and aspergillosis comparing Itraconazole DPI with Placebo (2 arms). Primary endpoint: Proportion of patients with proven or probable invasive mould disease at end of treatment. Started Dec 2019; status: completed.
02
Drugs
itraconazole
03
Conditions
Invasive mold disease (IMD)aspergillosis
Beyond the preview
Go deeper on 2019-002408-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002408-42.